Barclays PLC reduced its stake in Natera, Inc. (NASDAQ:NTRA - Free Report) by 53.6% during the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 140,115 shares of the medical research company's stock after selling 161,750 shares during the quarter. Barclays PLC owned about 0.11% of Natera worth $17,787,000 at the end of the most recent quarter.
A number of other large investors have also made changes to their positions in the stock. Wealth Enhancement Advisory Services LLC lifted its holdings in Natera by 59.6% in the 2nd quarter. Wealth Enhancement Advisory Services LLC now owns 9,218 shares of the medical research company's stock valued at $998,000 after purchasing an additional 3,442 shares in the last quarter. Envestnet Portfolio Solutions Inc. raised its position in shares of Natera by 50.6% in the second quarter. Envestnet Portfolio Solutions Inc. now owns 13,622 shares of the medical research company's stock valued at $1,475,000 after buying an additional 4,575 shares during the last quarter. Swedbank AB purchased a new position in shares of Natera during the second quarter valued at approximately $2,166,000. Sumitomo Mitsui Trust Holdings Inc. boosted its position in Natera by 39.5% during the second quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 517,941 shares of the medical research company's stock worth $56,088,000 after acquiring an additional 146,670 shares during the last quarter. Finally, First Citizens Bank & Trust Co. purchased a new stake in Natera in the 2nd quarter worth approximately $550,000. Institutional investors and hedge funds own 99.90% of the company's stock.
In other news, CEO Steven Leonard Chapman sold 5,024 shares of the firm's stock in a transaction dated Monday, September 16th. The shares were sold at an average price of $128.48, for a total value of $645,483.52. Following the transaction, the chief executive officer now directly owns 195,686 shares in the company, valued at approximately $25,141,737.28. This trade represents a 2.50 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, insider Solomon Moshkevich sold 1,196 shares of the company's stock in a transaction that occurred on Monday, October 28th. The shares were sold at an average price of $118.21, for a total value of $141,379.16. Following the transaction, the insider now directly owns 110,695 shares of the company's stock, valued at $13,085,255.95. This trade represents a 1.07 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 137,987 shares of company stock valued at $21,895,591 in the last three months. Corporate insiders own 7.60% of the company's stock.
Several research firms have recently issued reports on NTRA. StockNews.com cut Natera from a "hold" rating to a "sell" rating in a report on Thursday, November 14th. Robert W. Baird raised their price target on Natera from $120.00 to $160.00 and gave the stock an "outperform" rating in a research note on Wednesday, November 13th. JPMorgan Chase & Co. upped their price objective on shares of Natera from $160.00 to $200.00 and gave the company an "overweight" rating in a research note on Friday. Sanford C. Bernstein raised their target price on shares of Natera from $125.00 to $135.00 and gave the stock an "outperform" rating in a research report on Wednesday, October 30th. Finally, Canaccord Genuity Group boosted their target price on shares of Natera from $150.00 to $165.00 and gave the company a "buy" rating in a report on Wednesday, November 13th. One equities research analyst has rated the stock with a sell rating and fifteen have given a buy rating to the stock. Based on data from MarketBeat.com, Natera currently has an average rating of "Moderate Buy" and a consensus price target of $152.67.
View Our Latest Report on NTRA
Shares of NASDAQ NTRA opened at $166.55 on Friday. The company has a debt-to-equity ratio of 0.33, a current ratio of 4.39 and a quick ratio of 4.23. Natera, Inc. has a 1-year low of $57.22 and a 1-year high of $175.63. The company has a market capitalization of $21.99 billion, a price-to-earnings ratio of -94.63 and a beta of 1.63. The business has a 50-day moving average of $144.02 and a 200-day moving average of $124.56.
Natera (NASDAQ:NTRA - Get Free Report) last released its quarterly earnings results on Tuesday, November 12th. The medical research company reported ($0.26) earnings per share for the quarter, beating analysts' consensus estimates of ($0.57) by $0.31. Natera had a negative net margin of 14.01% and a negative return on equity of 26.23%. The business had revenue of $439.80 million during the quarter, compared to analyst estimates of $361.43 million. During the same period last year, the business earned ($0.95) EPS. The business's revenue was up 63.9% on a year-over-year basis. On average, equities analysts anticipate that Natera, Inc. will post -1.61 EPS for the current fiscal year.
Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Before you consider Natera, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Natera wasn't on the list.
While Natera currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.